A patient death in a phase 1 trial of Mersana Therapeutics’ antibody-drug ... which is developing the STING agonist in collaboration with GSK under the terms of a $1.3 billion option deal ...
a STING-agonist ADC developed using the Company's Immunosynthen platform. In addition, multiple partners are using Mersana's Dolaflexin platform to advance their ADC pipelines. Fintel is one of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback